Zim Laboratories Ltd

Zim Laboratories Ltd announced the allotment of 1,09,451 equity shares to eligible employees under the ZIM Laboratories Employee Stock Option Scheme (ESOS 2023). This allotment, approved via circular resolution on July 13, 2026, increases the company's paid-up equity share capital from Rs. 53,54,90,370 to Rs. 53,65,84,880. The new shares, with a face value of INR 10 each, were issued at an exercise price of INR 77.40 per share, realizing Rs. 84,71,507.40. The company confirmed these shares will rank pari-passu with existing equity shares.

Zim Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be closed effective from July 1, 2026, and will reopen 48 hours after the declaration of the company's financial results for the quarter ending June 30, 2026. This is a standard procedure to prevent potential insider trading during periods of sensitive financial information disclosure.

Zim Laboratories Ltd has disclosed an inter-se transfer of equity shares among its promoters. Dr. Anwar Daud acquired 80,000 equity shares, representing 0.15% of the diluted share capital, from Mr. Zulfiquar Kamal. The transaction, valued at INR 107.50 per share, falls under an exemption provided by Regulation 10(1)(a)(ii) of the SEBI SAST Regulations, thus not requiring an open offer. This move adjusts the shareholding percentages between the promoters, with Dr. Daud's stake increasing slightly to 25.05% and Mr. Kamal's decreasing to 2.08%.

Zim Laboratories Ltd has informed the stock exchanges that it has dispatched a letter to its members, providing the weblink to its Annual Report for the Financial Year 2025-26. This action is in compliance with Regulation 36(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The letter is specifically for those members who have not registered their email addresses. The company also announced its 42nd Annual General Meeting (AGM) scheduled for June 29, 2026, to be held via video conferencing. The filing also serves as a reminder for shareholders to update their KYC details as per recent SEBI circulars.

Zim Laboratories Ltd has filed its Annual Report for the Financial Year 2025-26, as per SEBI regulations. The report details the company's performance, strategic priorities for FY27, and its focus on patient-centric drug delivery solutions using Novel Drug Delivery Techniques. Key highlights include addressing EU-GMP remediation, strengthening quality systems, and advancing its differentiated product portfolio. The company also reported strengthening human resources and leadership capabilities with strategic hires in key positions to support global ambitions. The Annual Report is available on the company's website.

Zim Laboratories Ltd has announced its 42nd Annual General Meeting (AGM) to be held on Monday, June 29, 2026, at 11:30 a.m. IST via Video Conferencing. The company has also enclosed the Annual Report for the Financial Year 2025-26 along with the AGM notice. Key agenda items include the adoption of audited financial statements for FY26, re-appointment of a director, ratification of cost auditor remuneration, and approval for director remuneration in case of inadequate profits. The Register of Members and Share Transfer Book will be closed from June 23 to June 29, 2026.

Zim Laboratories Ltd. has disclosed a proposed inter-se transfer of 80,000 equity shares, representing 0.15% of its paid-up equity capital, between its promoters. Dr. Anwar Daud will acquire these shares from Mr. Zulfiquar Kamal. This off-market transaction qualifies for exemption under Regulation 10(1)(a)(ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquisition price will adhere to the limits specified in the regulations. The transfer is expected to take place on or after June 11, 2026, following the required four working days from the intimation date.

Zim Laboratories Ltd has announced its Q4 and FY26 earnings presentation. The company's FY26 total operating income decreased by 1.2% to ₹3,744 Mn, with EBITDA down 16.4% to ₹414 Mn. The EBITDA margin was 11.1%. Q4FY26 total operating income fell by 3.2% to ₹1,053 Mn, with EBITDA decreasing by 18.1% to ₹134 Mn and an EBITDA margin of 12.7%. Total R&D spend for FY26 was ₹311 Mn and ₹81 Mn for Q4FY26.

ZIM Laboratories Ltd has received Marketing Authorization (MA) from Agenzia Italiana del Farmaco (AIFA) for its anticoagulant product, Dabigatran Etexilate (75 mg, 110 mg & 150 mg hard capsules), in Italy via DCP to its wholly owned European subsidiary, SIA ZIM Laboratories Limited, Latvia. This authorization is expected to facilitate faster approvals in other European Union countries, the UK, and other global markets. Dabigatran Etexilate Capsules are used for the prevention and treatment of thromboembolic disorders. The EU market size for this product in 2025 was approximately USD 392.84 MN, with Italy contributing USD 60.91 MN.

Zim Laboratories Ltd has announced its audited standalone and consolidated financial results for the year ended March 31, 2026. The announcement follows a Board of Directors meeting held on May 19, 2026, where the results were reviewed and approved. Deloitte Haskins & Sells LLP issued an unmodified opinion on the financial results. The results are compliant with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.